Various ‘push-and-pull’ mechanisms have been tried to attract pharmaceutical companies into medical innovation for public ...

The US Food and Drug Administration (FDA) has granted priority review to AstraZeneca's supplemental biologics licence ...

AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression ...

The US Food and Drug Administration (FDA) has granted priority review to AstraZeneca's supplemental biologics licence application (sBLA) for Imfinzi (durvalumab), a human monoclonal antibody ...

If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of ...

AstraZeneca’s (AZN) supplemental biologics license application, or sBLA, for Imfinzi has been accepted and granted priority review in the U.S. for the treatment of patients with muscle-invasive ...

The Food and Drug Administration (FDA) has granted Priority Review to durvalumab for the treatment of adults with muscle-invasive bladder cancer (MIBC). The coprimary endpoints were pathological ...

December 06, 2024--(BUSINESS WIRE)--AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI ® (durvalumab) has been accepted and granted Priority Review in the US for the ...

Departments are set to have their spending plans scrutinised by "challenge panels" of external experts – including bankers, ...